Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.65 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.65 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 5/20 | 0.32 |
| ▸ | KIT | P10721 | 3/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
| ▸ | BLK | P51451 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | LYN | P07948 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28981114 | 1.00 | FGFR1 (0.65) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL31213850 | 0.95 | FGFR1 (0.73) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL31213925 | 0.91 | FGFR4 (0.60) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL28981101 | 0.90 | FGFR1 (0.52) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL30325778 | 0.90 | FGFR1 (0.52) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL31083196 | 0.90 | FGFR1 (0.61) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL28981109 | 0.90 | FGFR1 (0.54) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL30366793 | 0.90 | FGFR1 (0.54) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL31083384 | 0.90 | FGFR1 (0.68) | FGFR1FGFR2FGFR4FGFR3CYP3A4 | |
| SCHEMBL29265739 | 0.89 | FGFR1 (0.52) | FGFR1FGFR2FGFR4FGFR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | claimed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | claimed |
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4405358-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H Pharmaceuticals Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023046117-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383905-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR1, FGFR3, FGFR4 | FGFR1 1/4885FGFR2 4/4885FGFR4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.